Therapy Area topics

Cardiovascular

Central Nervous System

Diabetes

Vantage logo

The Wegovy wait continues

Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.

Digital Health

Oncology

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Respiratory

Various

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.